In a pre-clinical study, the same group has exploited this model by treating wild-type infected mice with odonacatib, an inhibitor of cathepsin K. Thus, they could pharmacologically achieve inactivity of cathepsin K. It was shown that odonacatib—a Cathepin K inhibitor that was withdrawn from the market due to side effects—treated mice were also protected against periodontitis (71). Here, CTSK is linked to periodontitis.